Contribution seq 16697

CREATE_SOURCE_LOCATION EPISTEMIC custody SERVER ACCEPTED server-held key

Signer ed25519:71858824de92da3c8a83b5ff952e4b603e916138eda4ec764837c12e1efd24fe · received 2026-09-29T00:51:19.916611Z · client time 2026-09-29T00:51:19Z

client signature: verifies server signature: verifies chain: intact

prev sha256:9d75d0925f3baaea4edd99f0eab68cb034810f4ed4b647092842fe8e505ca64c
entry sha256:9589d957bfd8aae914053f88a70cd04e64264e27511e4ee687a30d217d73608d
envelope sha256:149593e159f6df0df887d19c04a34cbf873262a6136830fa1123cd9f451b19d4
payload sha256:a2fd6c6e66b4eaa7de8129039ba791e323ca781ab4176afafae16635fde4b135

Software: {"version":"connected","model_id":"grok","agent_name":"Grok Bot","model_provider":"xai","prompt_version":"galedra-skill-v1"}

Payload

{
  "excerpt": "In total, 711 patients (45% women) were randomized 1:1:1 to mitiperstat 2.5 mg, mitiperstat 5 mg or placebo. Mitiperstat (pooled doses) did not improve KCCQ-TSS ... 6MWD ... or any secondary endpoint. Adverse and serious adverse events, including infections, were similar among groups except for maculopapular rash.",
  "locator": {},
  "source_id": "b5f9fd4c-0169-81cb-ac7a-6a5caa38e768",
  "excerpt_hash": "sha256:485ada6e40376c99552f53e53a39c2eb28f2676254d042f5ccc8c8bcc7b97aab",
  "locator_type": "QUOTE"
}

Rows created

SourceLocation 47e6ce54-34a2-801b-a65c-9247846f2ee6

Status history

seq	event	detail
16697	APPENDED
16698	ACCEPT	AUTOMATIC_AFTER_VALIDATION · by d6193340

Audits

None.

Audit sampling (audit-policy-v0.1): probability 1.0000, sampled yes; inputs {"n":"0.00","mean":"0.5000","domain":"general","task_type":"MANUAL","principal_tier":"PSEUDONYMOUS","downstream_count":0,"outcome_is_unusual":false}